peripheral artery disease

Through a genome-wide association study, a team of researchers from Riken uncovered three loci linked to peripheral artery disease susceptibility.

On a conference call last month following the release of its Q1 earnings, Vermillion CEO Thomas McLain announced that the company would be taking over from Quest Diagnostics as leader of commercialization efforts for its OVA1 ovarian cancer diagnostic (

Vermillion this week sent Quest Diagnostics a notice of default under the companies' Strategic Alliance Agreement relating to Vermillion's OVA1 and Vasclir diagnostic tests.

This story has been update to include comments from a Vermillion executive.

Vermillion this week reported essentially flat revenues for the third quarter of 2012 compared to the year-ago period.

This article has been updated from a version posted Oct. 12 to include additional information.

Vermillion last week reported results demonstrating the utility of its Vasclir protein biomarker test for peripheral artery disease.

This story originally ran on May 16.
Vermillion this week reported first-quarter 2012 revenues of $312,000, down 28 percent from $431,000 a year ago.

This story originally ran on Feb. 29 and has been updated to include comments from an investor.
By Adam Bonislawski

This story originally ran on Jan. 4 and has been updated to include additional information about company restructuring.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.